Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM0157T)

Drug Name
DM199 Drug Info
Indication
Disease Entry ICD 11 Status REF
Cerebral ischemia 8B11 Phase 2 [1]
Ischemic stroke 8B11.5Z Phase 2 [2]
Autoimmune diabetes 5A10 Phase 1/2 [3]
Diabetic nephropathy GB61.Z Phase 1/2 [4]
Cross-matching ID
TTD Drug ID
DM0157T

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B2 bradykinin receptor (BDKRB2) TTGY8IW BKRB2_HUMAN Activator [5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
B2 bradykinin receptor (BDKRB2) DTT BDKRB2 2.433 6.359 6.755 6.664
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Cerebral ischemia
ICD Disease Classification 8B11
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B2 bradykinin receptor (BDKRB2) DTT BDKRB2 6.64E-04 -0.24 -0.54
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04123613) Multiple Doses of DM199 in Patients With Chronic Kidney Disease. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01845064) A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients. U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT01845064) A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients. U.S. National Institutes of Health.
5 Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors. Pharmacol Res Perspect. 2015 Mar;3(2):e00119.